EUCTR2008-000876-26-FR进行中（未招募）不适用
VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCE
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Diagnosed with prostate cancer and eligible for active surveillance;
- •2.No prior treatment for prostate cancer;
- •3.Prostate Cancer Stage up to cT2b – N0/Nx – M0/Mx (rT2c and pT2c are acceptable);
- •4.Gleason score = 3+3 For patients characterized with prostate mapping (transperineal template guided biopsy at 5mm intervals) a secondary pattern 4 is acceptable provided that it is not present in more than 3 cores from each side of the prostate and is no more than 3 mm cancer core length.
- •5.PSA < 10 ng/mL;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.All patients whose current pre-operative cardiac evaluation does not show their fitness for a procedure requiring general anesthesia;
- •2.Patients with a history of inflammatory bowel disease or other factors which may increase the risk of fistula formation;
- •3.Men who have received any hormonal manipulation (excluding 5-alpha reductase inhibitors) or androgen supplements within the previous 6 months;
- •4.Men previously treated by radiation therapy (external therapy or brachytherapy) or chemotherapy or any therapy for prostate cancer;
- •5.Men who have received or are receiving chemotherapy for prostate carcinoma or other significant cancer;
- •6.Men who have undergone previous TURP (trans-urethral resection of the prostate);
- •7.Men who are currently (within the month before the treatment procedure) receiving any medications having potential photosensitizing effects (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics and griseofulvin);
- •8.Men who are currently receiving anticoagulant drugs (e.g.: coumadin, warfarin)
- •9.Patient who stopped long term treatment of acetylsalicylic acid (aspirin) or other anti platelets agents less than 15 days before the procedure;
- •10.Patient suspected of Disseminated Intravascular Coagulation (DIC) as defined by the presence of three out of the five following criteria: platelets decrease, increase of PT, increase of aPTT, fibrinogen decrease, D-Dimer increase.
- •11.A history of sun hypersensitivity or photosensitive dermatitis;
- •12.Renal disorders (blood creatinine > 1.5 x ULN) or known post mictional residue > 150cc
- •13.Hepatic disorders (transaminases > ULN, bilirubin > ULN, GGT > ULN). In case of slight abnormalities, another exam could be performed. If the results are within normal ranges, then the patient can be included;
- •14.Hematological disorders (white cells < 2500/mm3, neutrophils < 1500/mm3, platelets < 140.000/mm3, Hb < 8 g/dl);
研究者
相似试验
进行中（未招募）
不适用
VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCERocalized prostate cancerMedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2009-012809-19-NLSTEBA BIOTECH SA30
进行中（未招募）
1 期
VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCERocalized prostate cancerMedDRA version: 9.1 Level: LLT Classification code 10060862 Term: Prostate cancerEUCTR2009-012809-19-GBSTEBA BIOTECH SA30
进行中（未招募）
不适用
VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCEREUCTR2009-012809-19-FRSTEBA BIOTECH SA30
进行中（未招募）
1 期
VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCER”,The treatment of prostate cancerMedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerEUCTR2008-000876-26-GBSTEBA BIOTECH S.A.40
进行中（未招募）
不适用
Vascular-targeted photodynamic therapy using WST11 in patients with localised prostate cancerMedDRA version: 9.1Level: LLTClassification code 10060862Term: Prostate cancerProstate cancerEUCTR2008-000876-26-NLSTEBA BIOTECH N.V.24